首页|抗呕吐药5-HT3受体拮抗剂的经皮给药制剂研究进展

抗呕吐药5-HT3受体拮抗剂的经皮给药制剂研究进展

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
化疗所致恶心呕吐(chemotherapy induced nausea and vomiting,CINV)是肿瘤患者化疗过程中最常见的不良反应.5-HT3受体拮抗剂类药物被推荐为抗CINV的一线用药.但5-HT3受体拮抗剂药物目前临床常用剂型以口服和静脉给药为主,其中静脉注射给药易产生不良反应且需要专业医护操作,口服给药有首过效应,尤其是化疗后严重呕吐患者无法口服用药,所以目前临床常用剂型具有一定的缺陷,临床应用受到限制.经皮给药系统具有避免胃肠道首过效应、毒副作用小、病人依从性好等优点,所以抗肿瘤所致恶心呕吐药物的经皮给药系统受到人们的广泛关注和研究.本研究就5-HT3受体拮抗剂类药物的经皮给药制剂国内外研究现状进行综述,为该类药物的新制剂和新给药途径研发提供借鉴和参考.
Research Progress of Transdermal Delivery of Anti-Vomiting Drug 5-HT3 Receptor Antagonist
Chemotherapy induced nausea and vomiting(CINV)is the most common adverse reaction in cancer patients during chemotherapy.5-HT3 receptor antagonists are recommended as the first-line drugs against CINV.However,the commonly used clinical dosage forms of 5-HT3 receptor antagonists are mainly oral and intravenous administration,among which intravenous administration is easy to produce adverse reactions and requires professional medical operation.Oral administration has first-pass effect,especially for patients with severe vomiting after chemotherapy,so the commonly used clinical dosage forms have certain defects and limited clinical application.Transdermal drug delivery system has the advantages of avoiding gastrointestinal first-pass effect,less toxic and side effects,and good patient compliance,so the transdermal drug delivery system of anti-tumor nausea and vomiting drugs has been widely concerned and studied.In this paper,the research status of transdermal delivery of 5-HT3 receptor antagonists at home and abroad is reviewed,which provides reference for the research and development of new preparations and new delivery routes of these drugs.

cancer chemotherapynausea vomiting5-HT3 receptor antagonisttransdermal drug delivery

张旭、高秀容、王芊入、胡桃敏、蔡琴、吴星星、张涛、徐源

展开 >

成都医学院,成都 610083

四川省德昌县人民医院,四川凉山 615000

成都市郫都区人民医院,成都 611730

肿瘤化疗 恶心呕吐 5-HT3受体拮抗剂 经皮给药

成都医学院-成都市郫都区人民医院联合科研基金成都医学院大学生省级大学生创新创业训练计划四川省医学会青年创新科研课题成都医学院研究生创新科研基金项目凉山州科技计划重点研发科研课题

2021LHPJ-01S202213705078S22041YCX2023-01-4023ZDYF0069

2024

10.11669/cpj.2024.17.006

中国药学杂志
中国药学会

中国药学杂志

CSTPCD北大核心
影响因子：0.957
ISSN：1001-2494
年,卷(期)：2024.59(17)
  • 3